Article Details
Retrieved on: 2024-11-27 14:08:56
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Canaccord Genuity Group boosted their price target on BioNTech from $171.00 to $171.44 and gave the company a "buy" rating in a research note on ...
Article found on: www.marketbeat.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here